Colossal Biosciences is establishing standards for how biotechnology can responsibly support biodiversity conservation in an ...

CRISPR Cas9 gene therapy explained with DNA scissors, hereditary diseases treatment, and designer babies ethical dilemmas ...

Context for CRISPR Therapeutics stock CRISPR Therapeutics (CRSP) trades around US$49.51, with recent returns ranging from a 1 day gain of about 1.4% to a past month decline of roughly 13.6% and a past ...

We will know even more about the company's prospects in a year as it releases clinical data for various pipeline candidates.

Synthego, a pioneering leader in genome engineering solutions, today announced that the Supreme Court of the United States has denied a petition for a writ of certiorari from Agilent Technologies, Inc ...

Crispr Therapeutics AG looks set for 2026 revenue inflection as Casgevy ramps; strong efficacy, undervalued shares, robust ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

CRISPR Therapeutics AG (CRSP) is rated Buy, with a 12-month price target of $64.58, driven by CASGEVY's commercial ramp and a ...

A US patent board last week backed the Broad Institute’s claim to CRISPR use in human and animal cells, not the Nobel winners ...

View CRISPR Therapeutics AG CRSP stock quote prices, financial information, real-time forecasts, and company news from CNN.

One stock that's been on my watch list for a while is CRISPR Therapeutics (NASDAQ: CRSP). The company has an intriguing business, as not only could it generate a lot of revenue in the future, but it ...